[1] Conze, D., Brenner, C. & Kruger, C.L. Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults. Sci Rep 9, 9772 (2019).
[2] Belenky P, Bogan KL, Brenner C. NAD+ metabolism in health and disease [published correction appears in Trends Biochem Sci. 2008 Jan;33(1):1]. Trends Biochem Sci. 2007;32(1):12-19.
[3] Bogan KL, Brenner C. Nicotinic acid, nicotinamide, and nicotinamide riboside: a molecular evaluation of NAD+ precursor vitamins in human nutrition. Annu Rev Nutr. 2008;28:115-130.
4] Mehmel M, Jovanović N, Spitz U. Nicotinamide Riboside-The Current State of Research and Therapeutic Uses. Nutrients. 2020;12(6):1616. Published 2020 May 31.
[6] Rajman L, Chwalek K, Sinclair DA. Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence. Cell Metab. 2018;27(3):529-547.
[7] Aman, Yahyah & Qiu, Yumin & Tao, Jun & Fang, Evandro. (2018). Therapeutic potential of boosting NAD+ in aging and age-related diseases. Translational Medicine of Aging. 2. 10.1016/j.tma.2018.08.003.
[8] Katsyuba E, Auwerx J. Modulating NAD+ metabolism, from bench to bedside. EMBO J. 2017 Sep 15;36(18):2670-2683. doi: 10.15252/embj.201797135. Epub 2017 Aug 7.
[9] Wiley C, Campisi J. NAD+ controls neural stem cell fate in the aging brain. EMBO J. 2014;33(12):1289-1291. doi:10.15252/embj.201488969
[10] Lautrup S, Sinclair DA, Mattson MP, Fang EF. NAD+ in Brain Aging and Neurodegenerative Disorders. Cell Metab. 2019 Oct 1;30(4):630-655.